Acceleron Investors Want Merck To Pay More, Ask Company To Wait For Better Offer
$11.5bn Acquisition Values Firm At A 34%-38% Premium
Avoro Capital, Holocene Advisors and Darwin Global say that Acceleron should sell later for a higher price based on forthcoming data or Merck should raise its bid above $180 per share.
